

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/625,116	07/22/2003	Synese Jolidon	21229	9393
151	7590 01/25/2005		EXAMINER	
HOFFMANN-LA ROCHE INC. PATENT LAW DEPARTMENT 340 KINGSLAND STREET NUTLEY, NJ 07110			SHAMEEM, GOLAM M	
			ART UNIT	PAPER NUMBER
			1626	

DATE MAILED: 01/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/625,116	JOLIDON ET AL.				
Notice of Allowability	Examiner	Art Unit				
(Supplemental)	Golam M M Shameem	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to 8/11/2004.						
2. The allowed claim(s) is/are <u>1-46 and 53-55 (now 1-49)</u> .						
3. The drawings filed on are accepted by the Examiner.						
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☑ All b) ☐ Some* c) ☐ None of the:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).						
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Summar Paper No./Mail D 8), 7. ⊠ Examiner's Amend	ate				

DETAILED ACTION

Priority

This application claims benefit for foreign priority under 35 U.S.C. § 119(a)-(d) to European Patent Office (EPO) 02017676.4 08/07/2002, is acknowledged.

Status of Claims

Claims 1-46 and 53-55 are pending in the application.

Receipt is acknowledged of Applicant's amendment / response filed on August 11, 2004 and that has been entered.

Claims 47-52 and 56-60 are withdrawn from further consideration pursuant to 37 C.F.R. 1.142 (b) as being drawn to a non-elected subject matter.

Information Disclosure Statement

Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 10/20/03 and 01/16/2004, which has been entered in the file.

Response to Election/Restriction

In response to the restriction requirement, Applicants have elected Group I, (which includes claims 1-20, and 53-55) with traverse and the elected species as set forth in Example 15, on page 25 of the specification, is acknowledged.

During a telephonic interview, with Ms. Kimberly Prior (Attorney for Applicant) on August 30, 2004, Applicant has agreed to cancel non-elected claims 47-52 and 56-60. On the other hand, Examiner has agreed to rejoin Group II-IV (claims 21-46) with the elected Group I. Therefore, the requirement for restriction is still deemed proper and is therefore made FINAL.

Applicants preserve their right to file a divisional on the non-elected subject matter.

Examiner's amendment

An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's amendment was given in a telephone interview with Ms. Kimberly Prior on August 30, 2004.

The application has been amended as follows:

- a. Claims 47-52 and 56-60 have been canceled.
- b. In claim 21, page 40, delete "(Ia)" as formula identifier and insert with -- (I)-- for the same.

Reasons for allowance

The following is an examiner's statement of reasons for allowance:

McElroy et al (US 5,326,760) teach the aminobutanoic acid compounds, process for their preparation and methods of using thereof. The instant compound differs from the prior art by having a core of isoindole (wherein X is -CH=) ring, which is further substituted indirectly by different variables such as R¹, R², R³, and R⁴ etc that are selective monoamine oxidase inhibitors and are useful for treating diseases mediated by monoamine oxidase B. The prior art compound neither teaches nor renders obvious the instant claimed compound and there is no suggestion or motivation to modify the

compounds of other prior art to obtain the instantly claimed compounds. Therefore the instant claims 1-46 and 53-55 are allowable over the prior art of record.

The reference cited on the PTO-892 is included to show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (571) 272-0699. The Unofficial fax phone number for this Group is (703) 308-7922. The Official fax phone numbers for this Group are (703) 308-4556 or 305-3592.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Art Unit: 1626

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.

Golam M M Shameem, Ph.D. Primary Patent Examiner Art Unit 1626, Group 1620 Technology Center 1

January 5, 2005